Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Mr. E2u who wrote (10143)	1/26/2004 2:45:58 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

I looked briefly at GMED a while back. They believe that ARBs (angiotensin II receptor blockers) are a cure for everything. Even if they are correct (and I believe their claims are considerably exaggerated, although perhaps there is an interesting idea there, particularly for the treatment of SARS) there's the minor detail that all the approved ARBs (there are about half-a-dozen of them in the US) are patented drugs that belong to other companies. So it's hard to see how they would make any money on them. There's a reason most pink sheet stocks are on the pink sheets. Peter